secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002728
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.02, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx amends debt facility to $100M, draws $10M; Q4 rev ~$16M (+4-5% YoY)
------------------------------------------------------------------------

- Debt facility increased by $50M to $100M; $10M drawn at closing, total outstanding $60M; maturity extended to May 2031.
- Q4 2025 preliminary revenue $15.9-16.1M (+4-5% YoY); full-year 2025 revenue $56.5-56.7M (+10-11% YoY).
- FY2026 guidance: revenue $63-67M (+11-18% YoY); gross margin 84-86%; operating expenses $103-107M.
- BENEFIT-HF trial: FDA IDE granted Nov 2025; applied for CMS coverage; net trial costs $20-30M over 5-7 years.
- Cash and equivalents $75.7M as of Dec 31, 2025; 252 active implanting centers; 53 sales territories.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/tm262733d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer